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Copyright © 2004 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.03.018Postoperative bleeding is a common complication after prolonged cardiopulmonarybypass (CPB) with deep hypothermic circulatory arrest (DHCA).1 Experience in theoff-label use of recombinant factor VIIa (rFVIIa) after cardiac surgery under thecondition of DHCA is very limited, but a recent report demonstrated its efficacy in
a case of life-threatening bleeding after elective aortic arch repair in a patient without
preexisting hemorrhagic diathesis.2 We report a case of successfully using rFVIIa in the
treatment of severe intractable bleeding after emergency ascending and arch replacement for
acute type A aortic dissection with prolonged CPB and DHCA in a patient who received
antiplatelet drugs.
Clinical Summary
A 57-year-old man was admitted to another hospital for investigation into back pain and a
short episode of unconsciousness. Echocardiogram showed ST-segment elevation in the
posterior and inferior leads, and the patient received heparin 10,000 IU and aspirin 500 mg
(acetylsalicylic acid) for presumed myocardial infarction. Transesophageal echocardiogra-
phy, however, demonstrated a type A aortic dissection associated with a severe aortic valve
insufficiency, and the patient was intubated and referred to our center for surgical treatment.
On admission, the patient’s hemodynamic situation was stable under vasoactive support
with norepinephrine (0.05 g · kg1 · min1). Initial coagulation parameters were normal:
international normalized ratio, 1.2; activated partial thromboplastin time, 37 seconds; and
platelet count, 212  109/L. Chest computed tomographic findings confirmed the diagnosis
and showed a dissection that reached from the aortic valve to the femoral arteries. During
investigation, the patient’s hemodynamic state deteriorated, and he was taken to the operating
room without coronary angiography.
Anesthesia was maintained with 1.5% sevoflurane, supplemented with bolus doses of
fentanyl up to 10 g/kg and pancuronium 50 g/kg. Aprotinin 2  106 kallikrein-inhibitory
units (KIU) was administered before CPB was instituted, and another 2  106 KIU were
added to the CPB priming fluid, followed by a continuous infusion of 5  106 KIU/h for 6
hours. Activated clotting time was maintained at longer than 400 seconds during CPB, with
an initial heparin dose of 375 IU/kg and an 3 additional 5000 IU of heparin during bypass.
CPB was instituted by right subclavian artery and right atrial cannulation. After crossclamp-
ing of the ascending aorta, cardioplegic arrest was induced by selective coronary perfusion by
using Bretschneider crystalloid solution. The patient was cooled to 20°C tympanic temper-
ature, and extracorporeal circulation was stopped. After aortic arch incision, antegrade
cerebral perfusion was maintained by direct cannulation of the epiaortic vessels. Surgical
repair included distal end-to-end anastomosis of a 26  10-mm coated Dacron (DuPont,
Wilmington, Del) prothesis (Hemabridge; Intervascular, La Ciotat, France) to the descending
aorta and reinsertion of a patch of native aorti
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was established through a preformed branch graft. During rewarm-
ing, a modified Bentall procedure3 was performed with a valve-
bearing composite prothesis for aortic root replacement. End-to-
end anastomosis of the 2 grafts completed the surgical repair. The
CPB, selective cerebral perfusion, circulatory arrest, and aortic
crossclamping times were 191, 61, 45, and 132 minutes, respec-
tively. Weaning from CPB was easily achieved with dobutamine
(5 g · kg1 · min1) and norepinephrine (0.05 g · kg1 · min1)
but was complicated by abundant oozing from the multiple suture
sites. Even though activated clotting time returned to baseline
values (126 seconds) after administration of protamine, blood loss
persisted at an average rate of 110 mL/min. Desmopressin (0.3
g/kg) was given to treat the aspirin-induced platelet dysfunction.
Over the next 100 minutes, the patient also received 9 U of packed
red blood cells, 23 U of fresh frozen plasma, and 2 U of platelet
concentrate, in addition to 4000 mL of shed mediastinal blood,
without any therapeutic effect (Figure 1). Bioglue and 4 fibrin-
coated collagen fleeces (TachoComb; Nycomed, Linz, Austria)
were used without success by the surgeon to seal the oozing suture
sites. In this situation of persisting excessive bleeding without any
further chance of surgical intervention, we administered 9.6 mg
(90 g/kg) of rFVIIa. Bleeding decreased immediately in the next
few minutes, and the chest could be closed. After this single dose,
total blood loss from the chest drains decreased to a total of 850
mL over the next 24 hours. Coagulation parameters at arrival on
the intensive care unit were nearly normal: international normal-
Figure 1. Graphic representation of cumulative blood lo
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the patient received no additional blood products, was weaned
from inotropes, made a good recovery, and could be discharged
from the hospital on postoperative day 18.
Discussion
Bleeding complications after prolonged CPB are common, and
DHCA adds further damage to the coagulation system because it
involves more severe hypothermia and organ ischemia related to
blood stasis. In brief, a combination of platelet dysfunction, an
imbalance of fibrinolytic and antifibrinolytic systems, kinetic fac-
tors, and kinin/kallikrein perturbations all contribute to the coagu-
lopathy induced by hypothermia. The physiological response to
DHCA includes a thrombin-induced increase in activated protein
C that prevents clotting and maintains blood fluidity through
proteolysis of procoagulant factors Va and VIIIa and induction of
fibrinolysis by causing endothelial release of tissue plasminogen
activator.4
In the presented case, no metabolic disorders occurred, and the
patient’s hemodynamic situation was stable under mild inotropic
support during the period of bleeding. Nevertheless, the patient’s
temperature decreased from 36.7°C at separation from CPB to
35.2°C when rFVIIa was given, probably because of the excessive
bleeding, the open chest, and redistribution of cold blood out of
less perfused tissues after prolonged DHCA. Although hypother-
mia by itself could be responsible for coagulation disorders, rFVIIa
ransfusion requirements, and the patient’s temperature
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not reduced at 33°C compared with 37°C. However, the activity of
rFVIIa is considerably affected by pH (by 90% at 7.0 compared
with 7.4), and its efficacy may be reduced in acidotic patients.
Although rFVIIa was originally developed and licensed only
for treatment of bleeding in hemophilic patients with inhibitors, it
has been documented to control refractory hemorrhage after var-
ious types of surgery. Recombinant FVIIa acts by activating for-
mation of the prothrombinase complex and has a local action only
at sites of vascular injury where tissue factor and phospholipids are
exposed. Furthermore, rFVIIa can bind activated platelets. Bound
to the platelet surface, rFVIIa activates factor X and enhances the
amount of thrombin generated at the platelet surface. This tissue
factor–independent mechanism may explain the effectiveness of
rFVIIa in the treatment of bleeding episodes in patients with
aspirin-induced platelet function disorders.
In conclusion, this case suggest that rFVIIa could be applied
effectively to control refractory bleeding in hypothermic patients
with aspirin-induced platelet dysfunction after cardiac surgery in
DHCA, but the clinician must consider the level of acidosis present
before administration of rFVIIa. However, the drug is extremely
expensive, and on the basis of its mechanism of action, fatal
thrombosis is a potential risk.6 Therefore, rFVIIa should be applied
The Journal of Thoracivery judiciously and only in cases of life-threatening hemorrhage
without a surgical source in which all traditional means of treat-
ment have been exhausted.
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